#VRC01

Products based on broadly neutralizing antibodies could be used in HIV treatment and prevention.

The new coronavirus crisis has upended the clinical trials process around the world.

Researchers are trying to harness the power of certain antibodies as long-acting injectable forms of HIV treatment or PrEP.

Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.

People treated with VRC01 maintained undetectable viral load for up to 42 weeks after stopping antiretroviral therapy.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

Scientists succeed with new methods of spurring the immune system to manufacture broadly neutralizing antibodies against the virus.

A future form of pre-exposure prophylaxis (PrEP) may be an antibody infusion given every other month.